



ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use Disorders

November 3, 2016

— \$1 Million Awarded for the Development or Expansion of Innovative Programs Serving Mental Health and Addiction Communities —

DUBLIN--(BUSINESS WIRE)--Nov. 3, 2016-- [Alkermes plc](#) (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, today announced the company has awarded \$1 million in funds to non-profit patient and community organizations as part of its newly launched ALKERMES Inspiration Grants™ program. The competitive grant program was designed to fund innovative and high-impact programs to support people affected by mental health and substance use disorders.

"We have learned that our efforts to develop innovative new medicines to treat those affected by mental health and substance use disorders only address part of the needs of patients and their families," said Richard Pops, Chief Executive Officer of Alkermes. "To most effectively address the myriad of other needs of those suffering from addiction and mental illness, a whole societal infrastructure must be in place and operational. We often take this for granted, but services for these disease areas are desperately needed. This program seeks to support ideas within the community to catalyze change."

More than 300 proposals were received from local, regional and national non-profit organizations across the United States. Ten Innovation Grants (up to \$100,000) and five Emergence Grants (up to \$25,000) were awarded to programs demonstrating the potential for high-impact, an ability to be replicated across the ecosystem and/or inventive, and creative approaches to support the broader needs of people in the mental health and addiction communities. To view the full list of recipients and reviewers, please click [here](#).

"We found both the response to the program and the high quality of the submissions to be inspiring," commented Nikki Levy, Vice President of Patient Engagement at Alkermes. "We are excited to see the impact that the selected programs will make across the country and look forward to continuing the program next year. While we are only able to fund a limited number of the requests, we are confident that all of this year's applicants will continue to drive change and support people affected by serious mental illness and substance use disorders."

Awards went to large advocacy organizations, academic institutions and regional organizations. The selected programs include initiatives focused on peer support; connecting individuals to appropriate care, wellness and skill development in the criminal justice system; youth education and support services, as well as programs designed to help others understand the experience of individuals living with mental health conditions and substance use disorders.

"The National Sheriffs' Association (NSA) is honored, delighted and grateful to receive this prestigious award," said Timothy O. Woods, J.D., M.A., LL.M., Director of Grants & Contracts at the National Sheriffs' Association. "We thank Alkermes for this award to NSA and, moreover, for Alkermes' commitment to supporting the initiatives and good work of organizations nationwide through its creation of the ALKERMES Inspiration Grants program."

Selected programs were chosen by Alkermes in partnership with a group of external reviewers who represent the perspectives of the community. These reviewers included a patient advocate, a representative from the criminal justice system, a person in recovery and a caregiver. Proposals were evaluated based on a standard set of review criteria, which included potential impact, identification of need and creativity of the solution, the organization's ability to execute, and the sustainability of the program.

For more information on ALKERMES Inspiration Grants program, please visit www.alkermes.com/inspirationgrants.

About Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

ALKERMES Inspiration Grants™ is a trademark of Alkermes, Inc.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20161103005293/en/>

Source: Alkermes plc

Alkermes Contacts:

For Investors: Sandy Coombs, +1 781 609 6377

or

Eva Stroynowski, +1 781 609 6823

or

For Media:
Jennifer Snyder, +1 781 609 6166